Apex Hospitex And Neuroscience Profile
Key Indicators
- Authorised Capital ₹ 9.00 Cr
as on 16-12-2024
- Paid Up Capital ₹ 6.44 Cr
as on 16-12-2024
- Company Age 22 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 10.57%
(FY 2023)
- Profit -7.16%
(FY 2023)
- Ebitda -4.34%
(FY 2023)
- Net Worth 4.46%
(FY 2023)
- Total Assets 8.61%
(FY 2023)
About Apex Hospitex And Neuroscience
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.00 Cr and a paid-up capital of Rs 6.44 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kamal Mitra, Susanta Bhattacharya, Sandip Ray, and Ten other members serve as directors at the Company.
- CIN/LLPIN
U85110WB2002PTC094561
- Company No.
094561
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Apr 2002
- Date of AGM
09 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Apex Hospitex And Neuroscience?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujit Bhattacharyya  | Managing Director | 16-Jan-2023 | Current |
Board Members(12)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kamal Chatterjee | Director | 24-Feb-2012 | Current |
| Kamal Mitra | Director | 09-Jun-2010 | Current |
| Susanta Bhattacharya | Director | 30-Sep-2005 | Current |
| Sandip Ray | Director | 29-Jan-2006 | Current |
| Tapanendra Bhowmik | Director | 30-Sep-2005 | Current |
| Tirthankar Bhattacharya | Director | 01-Dec-2008 | Current |
Financial Performance of Apex Hospitex And Neuroscience.
Apex Hospitex And Neuroscience Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10.57% increase. The company also saw a slight decrease in profitability, with a 7.16% decrease in profit. The company's net worth moved up by a moderate rise of 4.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apex Hospitex And Neuroscience?
In 2023, Apex Hospitex And Neuroscience had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Synfratech Projects And Development LlpActive 13 years 5 monthsKamal Mitra and Susanta Bhattacharya are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Apex Hospitex And Neuroscience?
Unlock and access historical data on people associated with Apex Hospitex And Neuroscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apex Hospitex And Neuroscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apex Hospitex And Neuroscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
